In our study, the combination of all three mRNA expressions did not improve the prediction of clinically significant prostate cancer (AUC 0.74) compared to using PSMA and PCA3 alone (AUC 0.82 and 0.75, respectively) (Figure 2 and Figure 3). The gene discussed is FOLH1; the disease is prostate carcinoma.